An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986036 in Participants With Normal Hepatic Function and Participants With Moderate and Severe Hepatic Impairment
Latest Information Update: 17 Jun 2022
At a glance
- Drugs Pegbelfermin (Primary)
- Indications Fibrosis; Liver disorders; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 15 Jun 2022 Status changed from recruiting to completed.
- 29 Mar 2022 Planned End Date changed from 5 Jul 2021 to 13 Apr 2022.
- 29 Mar 2022 Planned primary completion date changed from 4 Jul 2021 to 12 Apr 2022.